Axsome Therapeutics已正式启动其候选药物Solriamfetol针对儿童注意缺陷多动障碍的Focus-2三期临床试验。这项研究旨在评估该药物在年轻患者群体中的安全性与有效性,标志着公司在该治疗领域研发进程中的一个重要里程碑。
Axsome Therapeutics已正式启动其候选药物Solriamfetol针对儿童注意缺陷多动障碍的Focus-2三期临床试验。这项研究旨在评估该药物在年轻患者群体中的安全性与有效性,标志着公司在该治疗领域研发进程中的一个重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.